Eli Lilly’s Oral GLP-1 Orforglipron Shows Average 27.3 lbs Weight Loss in Phase 3 Obesity Trial
Eli Lilly and Company has announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron, met the primary
